SCHEMBL3884518

SCHEMBL3884518

Cc1cccc(S(=O)(=O)c2ccccc2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 2/20 0.61
ALDH1A1 P00352 4/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
MAPT P10636 2/20 0.56
POLB P06746 1/20 0.56
KMT2A Q03164 2/20 0.53
HTT P42858 2/20 0.51
TDP1 Q9NUW8 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
CRHBP P24387 1/20 0.51
CRHR2 Q13324 1/20 0.51
MMP2 P08253 1/20 0.50
GAA P10253 1/20 0.50
ABCC9 O60706 1/20 0.49
ABCC8 Q09428 1/20 0.49
KCNJ11 Q14654 1/20 0.49
KCNJ8 Q15842 1/20 0.49
LMNA P02545 2/20 0.49
THRB P10828 1/20 0.49
TSHR P16473 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29468572 0.93 KMT2A (0.59) HTR6ALDH1A1SMN1; SMN2MAPTPOLB
SCHEMBL822302 0.93 KMT2A (0.59) HTR6ALDH1A1SMN1; SMN2MAPTPOLB
SCHEMBL20198361 0.92 ALDH1A1 (0.54) HTR6ALDH1A1SMN1; SMN2MAPTPOLB
Hydrochloric Acid SCHEMBL11279258 0.91 KMT2A (0.57) HTR6ALDH1A1SMN1; SMN2MAPTPOLB
SCHEMBL15607666 0.91 KMT2A (0.57) HTR6ALDH1A1SMN1; SMN2MAPTPOLB
SCHEMBL6151129 0.89 GAA (0.67) HTR6ALDH1A1SMN1; SMN2MAPTPOLB
SCHEMBL31038387 0.89 GAA (0.67) HTR6ALDH1A1SMN1; SMN2MAPTPOLB
(Phenylsulfonyl)Benzene SCHEMBL6912665 0.86 HTR6 (0.74) HTR6ALDH1A1SMN1; SMN2MAPTPOLB
SCHEMBL26291500 0.84 HTR6 (0.64) HTR6ALDH1A1SMN1; SMN2MAPTPOLB
SCHEMBL14735835 0.84 HTT (0.50) HTR6ALDH1A1SMN1; SMN2MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12100809-B2 Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery MITSUBISHI CHEMICAL CORPORATION (JP) 2024-09-24 US disclosed
US-20220149436-A1 NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY MITSUBISHI CHEMICAL CORPORATION (JP) 2022-05-12 US disclosed
US-11283107-B2 Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery MITSUBISHI CHEMICAL CORPORATION (JP) 2022-03-22 US disclosed
US-11078378-B2 Polyimide film, polyimide varnish, and product and layered product using the polyimide film ASAHI KASEI KABUSHIKI KAISHA (JP) 2021-08-03 US disclosed
US-20210028376-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2021-01-28 US disclosed
US-10593887-B2 Condensed cyclic compound and an organic light-emitting device including the same SAMSUNG DISPLAY CO., LTD. (KR) 2020-03-17 US disclosed
EP-3621141-A1 NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY MITSUBISHI CHEMICAL CORPORATION (JP) 2020-03-11 EP disclosed
US-20190229372-A1 NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY MITSUBISHI CHEMICAL CORPORATION (JP) 2019-07-25 US disclosed
US-10333172-B2 Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery MITSUBISHI CHEMICAL CORPORATION (JP) 2019-06-25 US disclosed
US-10290901-B2 2019-05-14 US disclosed
EP-2012386-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY Mitsubishi Chemical Corporation (JP) 2009-01-07 EP disclosed
EP-1373257-B9 INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES VERTEX PHARMA (US) 2008-10-15 EP disclosed
US-7323458-B1 Dihydrobenzodiazepins and their use for treating dyslipidemia MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2008-01-29 US disclosed
CN-1211367-C Prostaglandin agonists and their use to treat bone disorders PFIZER (US) 2005-07-20 CN disclosed
CN-1566096-A Prostaglandin agonists and their use to treat bonedisorders PFIZER (US) 2005-01-19 CN disclosed
US-6348631-B1 REACTING AROMATIC COMPOUND WITH ACYLATING OR SULFONYLATING AGENT IN PRESENCE OF FRIEDEL-CRAFTS CATALYST, WHEREIN ACYLATION OR SULFONYLATION REACTION IS CARRIED OUT IN LIQUID PHASE UNDER MICROWAVE IRRADIATION RHODIA CHIMIE (FR) 2002-02-19 US disclosed
CN-1275123-A Prostaglandin agonists and their use to treat bone disorders PFIZER (US) 2000-11-29 CN disclosed
EP-1019351-A1 METHOD FOR ACYLATION OR SULPHONATION OF AN AROMATIC COMPOUND RHODIA CHIMIE (FR) 2000-07-19 EP disclosed
WO-1998040339-A1 METHOD FOR ACYLATION OR SULPHONATION OF AN AROMATIC COMPOUND RHODIA CHIMIE (FR) 1998-09-17 WO disclosed
US-4788233-A REACTED WITH SYNTHETIC RUBBER, ADHESIVES, COATINGS SUNSTAR GIKEN KABUSHIKI KAISHA (JP) 1988-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10593887-B2 Condensed cyclic compound and an organic light-emitting device including the same CRY1, CRY2, CCNT1 HTR6 4079/4885ALDH1A1 322/4885SMN1; SMN2 4430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.